These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

756 related articles for article (PubMed ID: 34354255)

  • 1. Trends in kinase drug discovery: targets, indications and inhibitor design.
    Attwood MM; Fabbro D; Sokolov AV; Knapp S; Schiöth HB
    Nat Rev Drug Discov; 2021 Nov; 20(11):839-861. PubMed ID: 34354255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update.
    Roskoski R
    Pharmacol Res; 2021 Mar; 165():105463. PubMed ID: 33513356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.
    Roskoski R
    Pharmacol Res; 2020 Feb; 152():104609. PubMed ID: 31862477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules.
    Goebel GL; Qiu X; Wu P
    Trends Pharmacol Sci; 2022 Oct; 43(10):866-881. PubMed ID: 35589447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small molecule kinase inhibitors as anti-cancer therapeutics.
    Chahrour O; Cairns D; Omran Z
    Mini Rev Med Chem; 2012 May; 12(5):399-411. PubMed ID: 22303944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA-approved small molecule kinase inhibitors for cancer treatment (2001-2015): Medical indication, structural optimization, and binding mode Part I.
    Wang Y; Nan X; Duan Y; Wang Q; Liang Z; Yin H
    Bioorg Med Chem; 2024 Sep; 111():117870. PubMed ID: 39128361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives.
    Li J; Gong C; Zhou H; Liu J; Xia X; Ha W; Jiang Y; Liu Q; Xiong H
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinase drug discovery 20 years after imatinib: progress and future directions.
    Cohen P; Cross D; Jänne PA
    Nat Rev Drug Discov; 2021 Jul; 20(7):551-569. PubMed ID: 34002056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Properties of FDA-approved small molecule protein kinase inhibitors.
    Roskoski R
    Pharmacol Res; 2019 Jun; 144():19-50. PubMed ID: 30877063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A historical overview of protein kinases and their targeted small molecule inhibitors.
    Roskoski R
    Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-molecule kinase inhibitors: an analysis of FDA-approved drugs.
    Wu P; Nielsen TE; Clausen MH
    Drug Discov Today; 2016 Jan; 21(1):5-10. PubMed ID: 26210956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update.
    Roskoski R
    Pharmacol Res; 2022 Jan; 175():106037. PubMed ID: 34921994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The identification of new protein kinase inhibitors as targets in modern drug discovery.
    Akritopoulou-Zanze I
    IDrugs; 2006 Jul; 9(7):481-7. PubMed ID: 16821161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in the approval of cancer therapies by the FDA in the twenty-first century.
    Scott EC; Baines AC; Gong Y; Moore R; Pamuk GE; Saber H; Subedee A; Thompson MD; Xiao W; Pazdur R; Rao VA; Schneider J; Beaver JA
    Nat Rev Drug Discov; 2023 Aug; 22(8):625-640. PubMed ID: 37344568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies for the selective regulation of kinases with allosteric modulators: exploiting exclusive structural features.
    Fang Z; Grütter C; Rauh D
    ACS Chem Biol; 2013 Jan; 8(1):58-70. PubMed ID: 23249378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in GPCR drug discovery: new agents, targets and indications.
    Hauser AS; Attwood MM; Rask-Andersen M; Schiöth HB; Gloriam DE
    Nat Rev Drug Discov; 2017 Dec; 16(12):829-842. PubMed ID: 29075003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the cancer kinome through polypharmacology.
    Knight ZA; Lin H; Shokat KM
    Nat Rev Cancer; 2010 Feb; 10(2):130-7. PubMed ID: 20094047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs).
    Roskoski R
    Pharmacol Res; 2021 Mar; 165():105422. PubMed ID: 33434619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cross-sectional study of the FDA approved indications and supporting pivotal trials of small-molecular kinase inhibitors in cancer therapies with the biomarker of cancer driver gene.
    Huang Y; Xiong W; Ma L; Wu H
    Int J Cancer; 2022 Dec; 151(12):2107-2114. PubMed ID: 35860988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic protein kinase inhibitors.
    Grant SK
    Cell Mol Life Sci; 2009 Apr; 66(7):1163-77. PubMed ID: 19011754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.